NDAINJECTIONINJECTABLE
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
INAPSINE (droperidol) by Teva is clinical pharmacology droperidol produces marked tranquilization and sedation. First approved in 1970.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INAPSINE (droperidol) is a butyrophenone antipsychotic administered by injection that produces marked tranquilization, sedation, and antiemetic effects. It is approved for schizophrenia and works by antagonizing dopamine and producing alpha-adrenergic blockade with onset within 3-10 minutes. The drug maintains reflex alertness while inducing mental detachment and reduces nausea/vomiting during and after surgical procedures.
LOE Approaching
As an older injectable approaching loss of exclusivity, team size and marketing investment are likely minimal compared to peak-stage competitors.
Mechanism of Action
CLINICAL PHARMACOLOGY Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Worked on INAPSINE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.